ESTRO 2025 - Abstract Book

S1290

Clinical - Lung

ESTRO 2025

Of the 48 patients who received consolidation durvalumab, eight patients showed EGFR mutation-positive status. No significant differences in PFS and OS were observed between the EGFR mutation positive and negative groups (p = 0.441 and 0.299, respectively). Among patients with EGFR mutation positive status, there were no significant differences in PFS and OS between the PD-L1 positive and negative groups (Figure 2 upper stand). In addition, among patients with EGFR mutation negative status, there were no significant differences in PFS and OS between the PD-L1 positive and negative groups (Figure 2 lower stand).